Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Adaptive mutations of SARS-CoV-2 are rare and unlikely to be transmitted, but when they are transmitted they can have a big impact, finds a new study.

coronavirus

The study, led by Dr Katrina Lythgoe (Big Data Institute) and published today in Scienceused deep sequencing to obtain multiple SARS-CoV-2 genomic sequences per individual to characterise the genetic variation of their viral population.

The results indicate that acute SARS-CoV-2 infections tend to have few, if any, genetic variants. Even when mutations do arise, it will be hard for them to spread as most of the time only the most common variant will be passed on and the others will be lost. In rarer cases, a minority variant might get through and become the consensus sequence, or there might be co-transmission of multiple variants, leading to a mixed infection. This underlines the need to drive down the number of infections, making these rare events even rarer, and continued monitoring of SARS-CoV-2, so we can detect concerning new variants and act before they become dominant in a population.

Read more in a blog on the Fraser Group website.

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.